Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Minority Interest (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Minority Interest for 15 consecutive years, with -$5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Minority Interest fell 264.23% year-over-year to -$5.7 million, compared with a TTM value of -$5.7 million through Dec 2025, down 264.23%, and an annual FY2025 reading of $37.4 million, up 564.96% over the prior year.
  • Minority Interest was -$5.7 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $37.4 million in the prior quarter.
  • Across five years, Minority Interest topped out at $37.4 million in Q3 2025 and bottomed at -$5.7 million in Q4 2025.
  • Average Minority Interest over 4 years is $12.2 million, with a median of $13.3 million recorded in 2023.
  • Peak annual rise in Minority Interest hit 564.96% in 2025, while the deepest fall reached 264.23% in 2025.
  • Year by year, Minority Interest stood at $19.3 million in 2022, then crashed by 31.17% to $13.3 million in 2023, then crashed by 73.8% to $3.5 million in 2024, then tumbled by 264.23% to -$5.7 million in 2025.
  • Business Quant data shows Minority Interest for ARWR at -$5.7 million in Q4 2025, $37.4 million in Q3 2025, and -$2.5 million in Q2 2025.